At the same time, DKC1‐targeted ribosomal proteins suppressed the RAS/RAF/MEK/ERK pathway via interaction with HRAS, and combination therapy with PF and trametinib exhibited synergistic anticancer efficacy in colorectal cancer cells. This evidence concerns the gene DKC1 and colorectal cancer.